ARS Pharmaceuticals Inc (NASDAQ: SPRY) on Friday, soared 10.01% from the previous trading day, before settling in for the closing price of $9.89. Within the past 52 weeks, SPRY’s price has moved between $2.55 and $11.90.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -34.76%. The company achieved an average annual earnings per share of -6.43%. With a float of $47.60 million, this company’s outstanding shares have now reached $96.41 million.
The extent of productivity of a business whose workforce counts for 26 workers is very important to gauge.
ARS Pharmaceuticals Inc (SPRY) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of ARS Pharmaceuticals Inc is 50.90%, while institutional ownership is 35.70%. The most recent insider transaction that took place on Jul 16 ’24, was worth 1,140,295. In this transaction CHIEF MEDICAL OFFICER of this company sold 100,000 shares at a rate of $11.40, taking the stock ownership to the 1,547,447 shares. Before that another transaction happened on Jul 16 ’24, when Company’s PRESIDENT AND CEO sold 100,000 for $11.40, making the entire transaction worth $1,140,295. This insider now owns 1,547,447 shares in total.
ARS Pharmaceuticals Inc (SPRY) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.23 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -6.43% per share during the next fiscal year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
ARS Pharmaceuticals Inc (SPRY) is currently performing well based on its current performance indicators. A quick ratio of 32.78 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2109.41.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.47, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.58 in one year’s time.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
The latest stats from [ARS Pharmaceuticals Inc, SPRY] show that its last 5-days average volume of 1.19 million was superior to 0.61 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 49.33%. Additionally, its Average True Range was 0.71.
During the past 100 days, ARS Pharmaceuticals Inc’s (SPRY) raw stochastic average was set at 76.55%, which indicates a significant decrease from 79.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.02% in the past 14 days, which was higher than the 58.08% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.59, while its 200-day Moving Average is $7.64. Now, the first resistance to watch is $11.62. This is followed by the second major resistance level at $12.37. The third major resistance level sits at $13.34. If the price goes on to break the first support level at $9.90, it is likely to go to the next support level at $8.93. The third support level lies at $8.18 if the price breaches the second support level.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Key Stats
Market capitalization of the company is 1.05 billion based on 96,895K outstanding shares. Right now, sales total 30 K and income totals -54,370 K. The company made 0 K in profit during its latest quarter, and -10,290 K in sales during its previous quarter.
